Lincoln Capital Corp’s Akebia Therapeutics AKBA Stock Holding History

Lincoln Capital Corp’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,172	Closed	-$55K	–	60
2021 Q1	$55K	Sell	16,172 -4,990	-24%	-$18K	0.03%	57
2020 Q4	$59K	Hold	21,162	–	–	0.04%	54
2020 Q3	$53K	Buy	21,162 +5,152	+32%	+$45.2K	0.04%	55
2020 Q2	$217K	Sell	16,010 -7,756	-33%	-$80.2K	0.17%	44
2020 Q1	$180	Hold	23,766	–	–	0.08%	42
2019 Q4	$150K	Buy	23,766 +3,250	+16%	+$15.4K	0.11%	48
2019 Q3	$80K	Buy	20,516 +243	+1%	+$1.04K	0.07%	47
2019 Q2	$98K	Sell	20,273 -1,435	-7%	-$8.16K	0.09%	47
2019 Q1	$178K	Hold	21,708	–	–	0.16%	46
2018 Q4	$120K	Buy	+21,708	New	+$170K	0.11%	49

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lincoln Capital Corp's AKBA Position: Q2 2021 in Review

Lincoln Capital Corp sold out of Akebia Therapeutics (AKBA) in Q2 2021, closing a stake of 16,172 shares — an estimated $55K sold.

Lincoln Capital Corp first reported a position in AKBA in Q4 2018 and held it in 10 quarters. The position peaked at $217K in Q2 2020. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

Lincoln Capital Corp reported no remaining Akebia Therapeutics position as of Q2 2021 after selling out during the quarter.
Lincoln Capital Corp sold 16,172 Akebia Therapeutics shares in Q2 2021, an estimated $55K.
Lincoln Capital Corp first reported a position in Akebia Therapeutics in Q4 2018 and held it in 10 quarters.
Lincoln Capital Corp's Akebia Therapeutics position peaked at $217K in Q2 2020.
139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on Lincoln Capital Corp's 13F filing for Q2 2021, filed 22 Jul 2021.